Equities researchers at Piper Jaffray Companies started coverage on shares of TransEnterix (NYSEAMERICAN:TRXC) in a note issued to investors on Wednesday, MarketBeat.com reports. The firm set a “neutral” rating and a $1.60 price target on the medical instruments supplier’s stock. Piper Jaffray Companies’ target price suggests a potential upside of 32.23% from the company’s previous close.

A number of other research analysts also recently commented on the company. BTIG Research upgraded TransEnterix from a “neutral” rating to a “buy” rating and set a $3.00 price objective on the stock in a report on Tuesday, May 14th. Zacks Investment Research downgraded TransEnterix from a “hold” rating to a “sell” rating in a report on Wednesday, May 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. TransEnterix currently has a consensus rating of “Hold” and an average price target of $3.52.

TRXC opened at $1.21 on Wednesday. TransEnterix has a one year low of $1.03 and a one year high of $6.98.

TransEnterix (NYSEAMERICAN:TRXC) last released its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported ($0.09) EPS for the quarter, meeting analysts’ consensus estimates of ($0.09). The business had revenue of $2.18 million during the quarter, compared to analysts’ expectations of $4.50 million.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Hsbc Holdings PLC acquired a new stake in shares of TransEnterix in the 1st quarter valued at about $29,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of TransEnterix in the 4th quarter valued at about $29,000. Cetera Advisors LLC acquired a new stake in shares of TransEnterix in the 4th quarter valued at about $34,000. Whitnell & Co. acquired a new stake in shares of TransEnterix in the 1st quarter valued at about $35,000. Finally, BlueCrest Capital Management Ltd acquired a new stake in shares of TransEnterix in the 1st quarter valued at about $44,000.

TransEnterix Company Profile

TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.

Further Reading: What is the Producer Price Index (PPI)?

Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.